Table 2.

Clinical Trials of mTOR Inhibitors in Prostate Cancer

mTOR Inhibitor	Other Drugs Tested	Institution/Sponsor	Patients	Outcomes	Phase	Status
RAD-001a	Docetaxel Bevacizumab	Cedars-Sinai Medical Center, Novartis Pharmaceuticals, Genentech	Metastatic CRPC	Survival/response, safety	I/II	Enrolling
RAD-001b	Docetaxel	Dana-Farber Cancer Institute, Novartis Pharmaceuticals, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Oregon Health and Science University	Metastatic CRPC	Survival/response, safety	I/II	Enrolling
RAD-001c		Duke University	Metastatic CRPC	PSA response, changes in mTOR pathway (tissue bx)	II	Enrolling
RAD-001d	Bicalutamide	Dana-Farber Cancer Institute, Beth Israel Deaconess Medial Center, Novartis	CRPC	Survival/response, safety	II	Enrolling
RAD-001e	Gefitinib	Memorial Sloan-Kettering Cancer Center, NCI	Glioblastoma multiforme or metastatic CRPC	Survival/response, safety	I/II	Ongoing, not enrolling
AP23573f		Ariad Pharmaceuticals	Taxane-resistant CRPC	Survival/response, safety, molecular markers	II	Ongoing, not enrolling
CCI-779g		Jonsson Comprehensive Cancer Center, NCI	High risk newly dx'd CaP undergoing RP	mTOR pathway markers	II	Ongoing, not enrolling
CCI-779h		Wyeth Pharmaceuticals	Newly dx'd CaP undergoing RP	mTOR pathway markers	II	Completed
RAD-001i	Androgen deprivation	Sheba Medical Center	Intermediate or high-risk CaP undergoing RP or RadRx	mTOR pathway markers, time to biochemical failure	II	Not yet open
Rapamycinj		Sidney Kimmel Comprehensive Cancer Center, NCI	Intermediate or high-risk CaP undergoing RP	Safety, mTOR pathway markers, PSA response	I/II	Enrolling

^aGross, M.E. NCT00574769.

^bTaplin, M.E. NCT00459186.

^cGeorge, D.J. NCT00629525.

^dTaplin, ME. NCT00630344.

^eScher, H.I.; Rosen, N.; Abrey, L.E. NCT00085566.

^fBedrosian, C. NCT00110188.

^gSawyers, C. NCT00071968.

^hNCT00235794.

ⁱNCT00657982.

^jCarducci, M.A. NCT00311623.